Navigation Links
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model
Date:9/16/2008

Study Published in the Proceedings of the National Academy of Sciences

WALTHAM, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease. Treated animals showed superior motor performance by multiple measures, reduced loss of body weight, reduced brain atrophy and improved overall appearance compared to untreated animals. Huntington's mice were also analyzed for changes in the hundreds of genes whose expression in the brain is altered in the mouse model of Huntington's, as well as in humans with Huntington's disease. Using gene microarrays, the researchers identified genes in three brain regions whose expression was altered in the Huntington's mice and whose expression was altered by treatment with the HDAC inhibitor. Treatment partially normalized the expression level of approximately 90% of these genes with 32% being restored to normal levels. These results suggest that an HDAC inhibitor may be useful in treating Huntington's disease and that specific genes may be useful as biomarkers in clinical trials. The research was conducted using a compound that is covered by Repligen's exclusive license from The Scripps Research Institute. The study entitled "The HDAC Inhibitor 4b Ameliorates the Disease Phenotype and Transcriptional Abnormalities in Huntington's Disease Transgenic Mice" will be published the week of September 15, 200
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... On April 19th the Center for Disease ... the growing antibiotic resistant bacteria that may be lurking ... study were released late last month showing higher antibiotic ... years. For those suffering from bacteria driven acne, Probiotic ... in food, may eventually help breed acne causing bacteria. ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Expression Genetics, Inc.,(EGEN) announced today that ... selected as one of the Top 10 ... strategic partnering. The selection was made by,an ... leading,provider of business information products and services ...
... Development Efforts, SALT LAKE CITY, Sept. 5 ... development of molecular diagnostic and motion preserving,technologies in ... Ross has,joined the executive management team as the ... this new role, Ross will oversee Axial Biotech,s ...
... Ind., Sept. 4 Zimmer Holdings, Inc.,(NYSE: ZMH ... have,agreed to acquire the Abbott Spine business from Abbott ... to fund the purchase price,from cash on hand and ... expected to close in the fourth quarter of 2008. ...
Cached Biology Technology:Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 2Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 3Axial Biotech appoints new Vice President of Strategic Initiatives 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 3Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 4
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
(Date:5/22/2013)... discovery of potential environmental and human health effects ... each year has led scientists to recommend stronger ... of lithium-ion (Li-ion) battery materials. That,s the conclusion ... Environmental Science & Technology . , Oladele ... batteries have become mainstays for powering everything from ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... forests that add the most new growth each year -- ... Survey (USGS) study published in a recent issue of the ... forests will respond to ongoing and future environmental changes. , ... world¹s most productive forests may be those likely to respond ...
... DuPont polymer derived from a biological source, has been ... China Central Television (CCTV) as "Most Visionary Innovation" at ... DuPontTM Sorona® will receive the 2005 "New ... Global Plastics and Environmental Conference, sponsored by the Society ...
... core cellular mechanisms of sleep, researchers at University of ... a single gene mutation that has a powerful effect ... In its normal state, the Drosophila (fruit fly) gene, ... flow of potassium into cells, a process that critically ...
Cached Biology News:Live fast, die young true for forests too 2DuPont's first biologically derived polymer receives global recognition 2Wisconsin researchers identify sleep gene 2Wisconsin researchers identify sleep gene 3Wisconsin researchers identify sleep gene 4
Mouse Axl MAb (Clone 175128)...
Mouse GDF-8 Propeptide Affinity Purified Polyclonal Ab...
... Allen (1995) This book contains ... on current issues relating to the aetiology ... advances have been made recently which greatly ... include molecular neuropathology through clinical and diagnostic ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
Biology Products: